Juno Therapeutics, Inc. (JUNO) Reaches $54.20 After 6.00% Up Move; Delaware Investments Colorado Municipal Income Fund Has 1 Sentiment

December 6, 2017 - By Marguerite Chambers

The stock increased 0.07% or $0.01 during the last trading session, reaching $15.61. About 702 shares traded. Delaware Investments Colorado Municipal Income Fund, Inc. (VCF) has declined 5.81% since December 6, 2016 and is downtrending. It has underperformed by 22.51% the S&P500.

The stock of Juno Therapeutics, Inc. (NASDAQ:JUNO) is a huge mover today! The stock increased 1.88% or $1 during the last trading session, reaching $54.2. About 204,474 shares traded. Juno Therapeutics, Inc. (NASDAQ:JUNO) has declined 39.85% since December 6, 2016 and is downtrending. It has underperformed by 56.55% the S&P500.The move comes after 9 months positive chart setup for the $6.19 billion company. It was reported on Dec, 6 by Barchart.com. We have $57.45 PT which if reached, will make NASDAQ:JUNO worth $371.28M more.

Investors sentiment increased to 1.33 in Q2 2017. Its up 0.22, from 1.11 in 2017Q1. It improved, as 21 investors sold Juno Therapeutics, Inc. shares while 40 reduced holdings. 38 funds opened positions while 43 raised stakes. 53.50 million shares or 13.76% more from 47.03 million shares in 2017Q1 were reported. State Of Wisconsin Invest Board has 0% invested in Juno Therapeutics, Inc. (NASDAQ:JUNO) for 12,562 shares. 10,810 were accumulated by Pub Employees Retirement Association Of Colorado. Td Asset Mgmt Inc reported 0% of its portfolio in Juno Therapeutics, Inc. (NASDAQ:JUNO). Fincl Bank Of America De has 47,028 shares for 0% of their portfolio. Balyasny Asset Mngmt invested 0.02% of its portfolio in Juno Therapeutics, Inc. (NASDAQ:JUNO). Redmile Group Limited Com invested 4.04% in Juno Therapeutics, Inc. (NASDAQ:JUNO). Lenox Wealth Management reported 100 shares. Mitsubishi Ufj Trust Banking Corp owns 901,750 shares. Principal Financial Gp holds 0% of its portfolio in Juno Therapeutics, Inc. (NASDAQ:JUNO) for 8,655 shares. Metropolitan Life Communications Ny stated it has 0% of its portfolio in Juno Therapeutics, Inc. (NASDAQ:JUNO). Ny State Common Retirement Fund invested in 0.01% or 137,700 shares. Macquarie Ltd invested 0% of its portfolio in Juno Therapeutics, Inc. (NASDAQ:JUNO). Tradewinds Ltd Liability reported 28 shares. Two Sigma Securities Limited Liability accumulated 0.09% or 15,925 shares. Artal Grp Sa accumulated 200,000 shares.

Among 16 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 10 have Buy rating, 1 Sell and 5 Hold. Therefore 63% are positive. Juno Therapeutics Inc had 43 analyst reports since July 22, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Tuesday, August 18 by FBR Capital. On Monday, August 24 the stock rating was initiated by Standpoint Research with “Buy”. The stock of Juno Therapeutics, Inc. (NASDAQ:JUNO) has “Outperform” rating given on Tuesday, August 29 by Wedbush. Maxim Group maintained Juno Therapeutics, Inc. (NASDAQ:JUNO) rating on Friday, August 5. Maxim Group has “Buy” rating and $50 target. On Monday, August 28 the stock rating was upgraded by BTIG Research to “Hold”. The stock of Juno Therapeutics, Inc. (NASDAQ:JUNO) earned “Buy” rating by Raymond James on Friday, November 3. Raymond James downgraded the stock to “Mkt Perform” rating in Tuesday, December 6 report. Barclays Capital initiated the stock with “Equal-Weight” rating in Wednesday, July 6 report. The rating was downgraded by Standpoint Research on Thursday, August 31 to “Reduce”. On Thursday, November 2 the stock rating was upgraded by SunTrust to “Buy”.

Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell cancer immunotherapies. The company has market cap of $6.19 billion. The firm develops cell cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. The Company’s CD19 product candidates include JCAR017 that is in Phase I/II trials for adults with relapsed or refractory B cell aggressive non-Hodgkin lymphoma (NHL) and pediatric patients with r/r B cell acute lymphoblastic leukemia (ALL); JCAR014, which is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies; and JCAR015 that is in Phase II trials for adult patients with r/r ALL.

Analysts await Juno Therapeutics, Inc. (NASDAQ:JUNO) to report earnings on March, 7. They expect $-1.02 earnings per share, down 54.55% or $0.36 from last year’s $-0.66 per share. After $-1.12 actual earnings per share reported by Juno Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -8.93% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: